Drugs / Allogeneic mesenchymal stem cells (MSCs)
Allogeneic mesenchymal stem cells (MSCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06231771 | May → Oct 2024 | ulcer of lower limbs | Supergenics Life Science Sdn. Bhd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic mesenchymal stem cells (MSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06231771 ↗ |
| Modality | Cell therapy | “using Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs)” NCT06231771 ↗ |
| Route | Other | “The administration of the product will be through the peri-ulcer route.” NCT06231771 ↗ |